

F2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/43494 A2(51) International Patent Classification⁷: A01N 53/00 // (A01N 53/00, 51:00)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US01/44084

(22) International Filing Date:
26 November 2001 (26.11.2001)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
09/727,117 30 November 2000 (30.11.2000) US

(71) Applicant: BAYER CORPORATION [US/US]; 100 Bayer Road, Pittsburgh, PA 15205-9741 (US).

(72) Inventor: ARTHUR, Robert, G.; 8103 Sagamore, Leawood, KS 66206 (US).

(74) Agents: AKORLI, Godfried, R. et al.; Bayer Corporation, 100 Bayer Road, Pittsburgh, PA 15205-9741 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/43494 A2

(54) Title: COMPOSITIONS FOR ENHANCED ACARICIDAL ACTIVITY

(57) Abstract: A composition for control of parasitic insects and acarids, comprising a combination of pyrethroids and chloronicotinyl compounds.

COMPOSITIONS FOR ENHANCED ACARICIDAL ACTIVITY

BACKGROUND OF THE INVENTION

Field of the Invention: The present invention relates to compositions for controlling certain parasitic insects, and acarids by means of a combination of pyrethroids and nicotinyl compounds. More specifically, the invention relates to compositions comprising a combination of 5 pyrethroids and chloronicotinyl compounds, which produce enhanced activity against acarids, particularly ticks and mites on mammals, and on premises.

Brief Description of the Prior Art: Of particular interest here are compositions that are effective against insects such as fleas and acarids 10 such as ticks and mites. Pyrethroids are known to be useful against acarids. Illustratively, U.S. Patent 5,236,954 discloses a liquid phase composition of a pyrethroid in concentrations greater than 50% w/w that may be used as basis for other pyrethroid-containing formulations in physical phases other than the liquid phase and methods of using the 15 same as parasiticides. Also, nicotinyl compounds, particularly chloronicotinyl, are known to be effective against fleas. PCT application WO 93/24 002 discloses that certain 1-[N-(halo-3-pyridylmethyl)]-N-methylamino-1-alkylamino-2-nitroethylene derivatives are suitable for systemic use against fleas in domestic animals. U.S. Patent 6,001,858, 20 discloses the dermal application of chloronicotinyl compounds, which are particularly suitable for control of parasitic insects such as fleas, lice or flies on animals.

It was, however, not known whether the addition of pyrethroids to nicotinyl compounds would enhance the activity of the pyrethroids without 25 adversely affecting the activity of the latter against fleas. Surprisingly, the combination of the pyrethroids and nicotinyl compounds has been found to produce enhanced acaricidal activity as well as maintain continued excellent activity against fleas.

SUMMARY OF THE INVENTION

In accordance with the foregoing, the present invention encompasses a composition for controlling parasitic insects and acarids containing a combination of active ingredients comprising pyrethroids and 5 nicotinyl compounds. The composition is particularly suitable for dermal control of parasitic acarids and insects, particularly ticks, mites and fleas on mammals, as well, as premise control of fleas, ticks and mites and other susceptible insects. By the term "control" or "controlling" herein is meant rendering the insects and acarids innocuous, preferably by killing 10 the insect and acarids to the extent that at least 80% die within days, and preferably within 2 days of application. In the preferred embodiment, the treated target is infested with insects and/or acarids. By the term combination is meant a regimen of applying the two active ingredients, either together or separately but concurrently.

15 In the presently preferred embodiment, the invention encompasses a composition comprising a combination of permethrin and imidacloprid. It has been found that the combination of these active ingredients produces a synergistic effect of significantly enhancing onset of activity (control) against acarids such as ticks and mites, and long-term activity (control) against ticks and fleas. This is rather unexpected because imidacloprid or permethrin alone generally has limited activity against acarids such as ticks and mites, and permethrin alone, generally, has limited and short duration of activity against fleas. Surprisingly, imidacloprid in combination 20 with permethrin has been found to significantly enhance the kill activity against these parasites, and thus provides excellent control. Moreover, in the use of the combination against fleas, imidacloprid activity has not been negatively affected by the permethrin. The invention is described more 25 fully hereunder.

DETAILED DESCRIPTION OF THE INVENTION

30 As set forth above, the invention relates to a composition comprising a combination of pyrethroids and chloronicotinyl compounds in effective concentrations to provide enhanced acaricidal activity without

producing a detrimental effect on the activity of nicotinyl compounds on fleas. Pyrethroid insecticides including such compounds as permethrin, cyfluthrin, flumethrin and fenvalerate are more stable synthetic analogues of the naturally occurring pyrethrins. Pyrethroids bind to the membrane receptors along the nerve axon, causing prolonged opening of the sodium channels, resulting in prolonged depolarization, repetitive nerve firing and synaptic disturbances leading to hyperexcitatory symptoms. Nicotinyl compounds have a distinct mode of action with biological activities that are different anatomically and physiologically from the pyrethroids. They bind to the nicotinergic receptors in the post-synaptic nerve region, which prevents acetylcholine chemical transmitter of signals between nerves from binding and transmitting signals. Reportedly, the chloronicotinyl compounds are more specific than pyrethroids for the binding sites on insect nerves than acarids or vertebrates.


Without being bound to any particular theory of the invention, it is believed that the nicotinyl compounds do not bind to sufficient number of receptor sites on acarid post-synaptic nerve locations to provide activity. The chloronicotinyl compounds are, therefore, ineffective or only marginally active against ticks and mites.

Surprisingly, the combination of a pyrethroid and a chloronicotinyl insecticide provides enhanced activity against ticks and mites, while maintaining the activity of chloronicotinyl compounds against fleas. The enhanced activity is most notable when the two compounds are first applied producing a faster kill of acarids than permethrin alone and then again at the end of the effective treatment duration when the effects of the pyrethroid alone begins to decline.

Illustrative but non-limiting examples of pyrethroids are permethrin, phenethrin, cypermethrin, cyhalothrin, lambda cyhalothrin, cyfluthrin, cyphenothrin, tralomethrin, tralocythrin, deltamethrin, slubalinate, fluvalinate, flumethrin and fenvalerate. Preferred herein is permethrin, [(3-phenoxy-phenyl)methyl-3-(92,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate].

Chloronicotinyl compounds are known, for example, from European Offenlegungsschriften (European Published Applications) Nos. 580 553, 464 830, 428 941, 425 978, 386 565, 383 091, 375 907, 364 844, 315 826, 259 738, 254 859, 235 725, 212 600, 192 060, 163 855, 154 178, 136 636, 5 303 570, 302 833, 306 696, 189 972, 455 000, 135 956, 471 372, 302 389; German Offen-legungsschriften (German Published Specifications) Nos. 3 639 877, 3 712 307; Japanese Offenlegungs-schriften (Japanese Published Applications) Nos. 03 220 176, 02 207 083, 63 307 857, 63 287 764, 03 246 283, 04 9371, 03 279 359, 03 255 072, U.S. Patents 10 5,034,524, 4,948,798, 4,918,086, 5,039,686 and 5,034,404; PCT Applications Nos. WO 91/17 659, 91/4965; French Application No. 2 611 114; and Brazilian Application No. 88 03 621. The compounds described in these publications and their preparation are hereby expressly incorporated herein by reference.

15 These compounds can be advantageously represented by the general formula (I)



in which

R represents, hydrogen, optionally, substituted radicals from acyl, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl;

25 A represents a monofunctional group from hydrogen, acyl, alkyl, aryl, or represents a bifunctional group which is linked to the radical Z;

E represents an electron-withdrawing radical;

X represents the radicals $-\text{CH}=$ or $=\text{N}-$, it being possible for the radical $-\text{CH}=$ instead of an H atom to be linked to the radical Z;

30 Z represents a monofunctional group from alkyl, $-\text{O}-\text{R}$, $-\text{S}-\text{R}$,



Particularly preferred compounds of the formula (I) are those in which the radicals have the following meaning:

R represents hydrogen and represents optionally substituted radicals from acyl, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl.

5 Acyl radicals which may be mentioned are formyl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, (alkyl)-(aryl)-phosphoryl, which may in turn be substituted.

As alkyl there may be mentioned C₁₋₁₀-alkyl, especially C₁₋₄-alkyl, specifically methyl, ethyl, i-propyl, sec- or t-butyl, which may in turn 10 be substituted.

As aryl there may be mentioned phenyl or naphthyl, especially phenyl.

As aralkyl there may be mentioned phenylmethyl or phenethyl.

As heteroaryl there may be mentioned heteroaryl having up to 10 15 ring atoms and N, O or S, especially N, as hetero atoms. Specifically there may be mentioned thienyl, furyl, thiazolyl, imidazolyl, pyridyl and benzothiazolyl.

As heteroarylalkyl there may be mentioned heteroarylmethyl or heteroarylethyl having up to 6 ring atoms and N, O or S, especially N, as 20 hetero atoms.

Substituents which may be listed by way of example and preference are:

25 alkyl having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methyl, ethyl, n- and i-propyl and n-, i- and t-butyl; alkoxy having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methoxy, ethoxy, n- and i-propoxy and n-, i- and t-butyloxy; alkylthio having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methylthio, ethylthio, n- and i-propylthio and n-, i- and t-butylthio; halogenoalkyl having preferably 1 to 4, in particular 1 or 2 30 carbon atoms and preferably 1 to 5, in particular 1 to 3 halogen atoms, the halogen atoms being identical or different and being preferably fluorine, chlorine or bromine, especially fluorine, such as

trifluoromethyl; hydroxyl; halogen, preferably fluorine, chlorine, bromine and iodine, especially fluorine, chlorine and bromine; cyano; nitro; amino; monoalkyl- and dialkylamino having preferably 1 to 4, in particular 1 or 2 carbon atoms per alkyl group, such as 5 methylamino, methyl-ethyl-amino, n- and i-propylamino and methyl-n-butylamino; carboxyl; carbalkoxy having preferably 2 to 4, in particular 2 or 3 carbon atoms, such as carbomethoxy and carboethoxy; sulpho (-SO₃H); alkylsulfonyl having preferably 1 to 4, in particular 1 or 2 carbon atoms, such as methylsulfonyl and 10 ethylsulfonyl; arylsulfonyl having preferably 6 or 10 aryl carbon atoms, such as phenylsulfonyl, and also heteroaryl amino and heteroarylalkylamino such as chloropyridylamino and chloropyridyl-methylamino.

A particularly preferably represents hydrogen and represents 15 optionally substituted radicals from acyl, alkyl or aryl, which preferably have the meanings given for R. A additionally represents a bifunctional group. There may be mentioned optionally substituted alkylene having 1-4, in particular 1-2 C atoms, substituents which may be mentioned being the substituents listed earlier above, and it being possible for the alkylene 20 groups to be interrupted by hetero atoms from the group consisting of N, O or S.

A and Z may, together with the atoms to which they are attached, form a saturated or unsaturated heterocyclic ring. The heterocyclic ring can contain a further 1 or 2 identical or different hetero atoms and/or 25 hetero groups. Hetero atoms are preferably oxygen, sulfur or nitrogen, and hetero groups are preferably N-alkyl, where the alkyl in the N-alkyl group preferably contains 1 to 4, in particular 1 or 2 carbon atoms. As alkyl there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6 ring members.

30 Examples of the heterocyclic ring which may be mentioned are imidazolidine, pyrrolidine, piperidine, piperazine, hexamethyleneimine,

hexahydro-1,3,5-triazine, hexahydroooxodiazine and morpholine, each of which may optionally be substituted, preferably by methyl.

E represents an electron-withdrawing radical, in which context particular mention may be made of NO_2 , CN and halogenoalkyl-
5 carbonyl such as 1,5-halogeno-C₁₋₄-carbonyl, especially COCF_3 .

X represents -CH= or -N=

Z represents optionally substituted radicals alkyl, -OR, -SR or -NRR, where R and the substituents preferably have the meaning given above.


10 Z can form, apart from the above-mentioned ring, and together with the atom to which it is attached and with the radical =C- instead of X, a saturated or unsaturated heterocyclic ring. The heterocyclic ring can contain a further 1 or 2 identical or different hetero atoms and/or groups. The hetero atoms are preferably oxygen, sulfur or nitrogen, and the hetero groups are preferably N-alkyl, in which case the alkyl or N-alkyl group preferably contains 1 to 4, in particular 1 or 2 carbon atoms. As alkyl there may be mentioned methyl, ethyl, n- and i-propyl and n-, i- and t-butyl. The heterocyclic ring contains 5 to 7, preferably 5 or 6 ring members.
15


20 Examples of the heterocyclic ring which may be mentioned are pyrrolidine, piperidine, piperazine, hexamethyleneimine, morpholine and N-methylpiperazine.

Particularly preferred are compounds of the general formulae (II) and (III):

25

30



















in which


n represents 1 or 2,

10 Subst. represents one of the above-listed substituents, especially halogen,
very particularly chlorine,
A, Z, X and E have the meanings given above.

Specifically, the following compounds may be mentioned:







In the method of preparing the composition of the invention, the
 25 active ingredients can be combined in any convenient manner such as in
 an aqueous solution, suspension or emulsion or solid matrices such as ear
 tags or collars. Preferably, both active ingredients are soluble in one or
 more solvents used in the formulation. The active ingredients may be
 combined by mixing with extenders such as liquid solvents, pressurized
 30 liquified gases and/or solid carriers, optionally with the use of surfactants.

The concentration of the active ingredients in the composition or
 formulation is such as is effective to control the parasitic insects or acarids.
 The particular concentration would depend on the form of the formulation
 and the method of application. Typically, the pyrethroid can be present in

concentrations of from 0.1% to 60% w/w depending on the use (premise or dermal application on mammals) and preferably from 40% to 60% (w/w) for dermal application to mammals. The nicotinyl compounds can be present in concentrations of 0.001% to 60% (w/w) depending on the use

5 (premise or dermal application on mammals) and preferably from 0.1% to 25% (w/w) for dermal application on mammals. Most preferably, the composition comprises at least 40% (w/w) permethrin and 8-10% (w/w) imidacloprid. Preparations which are diluted before use contain the active substance in concentrations of from 0.1% (w/w) to 90% (w/w). For dermal

10 application to animals, the formulation preferably contains from 0.1% (w/w) to 25% (w/w), preferably from 5% (w/w) to 20% (w/w). Given the teachings herein, it will be within the purview of the skilled artisan to select the type and concentration of pyrethroids that are not toxic to mammals, particularly cats.

15 Solvents useful herein can be selected from the group consisting of but not limited to water, oils, pyrrolidones, alcohols and cyclic carbonates; optionally with co-solvents from similar groups. Preferred oils include light mineral oil and vegetable oils. Preferred pyrrolidones include but are not limited to N-methyl pyrrolidone. Preferred alcohols include but are not

20 limited to aromatic or aliphatic alcohols such as glycols, benzyl alcohol, isopropanol, ethanol, diethylene glycol, propylene glycol, 2-octyl-1-dodecanol and tetrahydrofurfuryl alcohol. They are present in a concentration of at least 0.01 to 95% by weight, preferably from 1 to 30% by weight, particularly preferably from 1 to 20% by weight. Preferred cyclic

25 carbonates are ethylene carbonate and propylene carbonate. Particular preferred is propylene carbonate which can be present in a concentration of from 2.5 to 99.9999% by weight, preferably from 7.5 to 90% by weight, particularly preferably from 10 to 90% by weight.

Suitable further auxiliaries are: preservatives such as benzyl alcohol

30 (not required if already present as solvent), trichlorobutanol, p-hydroxybenzoic esters, n-butanol, piperonyl butoxide and water as solubility enhancer. They are present in a concentration of from 0 to 15% by weight,

preferably from 2.5 to 12.5% by weight, particularly from 2.5 to 10.0% by weight. The sum of active compounds, solvents and auxiliaries has to be 100% by weight.

Thickeners are, for example, inorganic thickeners such as 5 bentonites, colloidal silicic acid, aluminum monostearate, organic thickeners such as cellulose derivatives, polyvinyl alcohols, polyvinylpyrrolidones and copolymers thereof, acrylates and methacrylates.

Colorants useful herein are those approved for use in drugs which 10 may be dissolved or suspended.

Spreading agents include but are not limited to oils such as di-2-ethylhexyl adipate, isopropyl myristate, dipropylene glycol pelargonate, cyclic and acyclic silicone oils such as dimeticones and also co- and terpolymers thereof with ethylene oxide, propylene oxide and formalin, 15 fatty acid esters, triglycerides and fatty alcohols.

Antioxidants are, for example, sulfites or metabisulfites such as potassium metabisulfite, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol. Light stabilizers are, for example, substances from the class of the benzophenones or Novantisol acid. 20 Adhesives are, for example, polymeric thickeners, for example, cellulose derivatives, starch derivatives, polyacrylates, naturally occurring polymers such as alginates and gelatin.

Auxiliaries are also emulsifiers such as nonionic surfactants, for example polyoxyethylated castor oil, polyoxyethylated sorbitan 25 monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ethers; amphotolytic surfactants such as disodium N-lauryl-β-iminodipropionate or lecithin; anionic surfactants such as sodium lauryl sulfate, fatty alcohol ether sulfates, mono/dialkyl-polyglycol ether orthophosphoric ester monoethanolamine salt; and 30 cationic surfactants such as cetyltrimethylammonium chloride.

While being of low toxicity to warm-blooded species, the formulations according to the invention are suitable for the control of

parasitic insects which are encountered on premises, and animals including dogs, cats, horses, cattle, swine, sheep and humans. They are active against all or individual stages of development of the pests and against resistant and normally sensitive species of the pests.

5 In the practice of the invention, the composition can be applied in any convenient manner. In dermal applications, for example, the composition can be applied by dropping a small but effective volume at a spot on the animal. In the present embodiment of the invention, synergistic results are obtained when the active ingredients are applied
10 concurrently as separate formulations. A combination of the pyrethroids and nicotinyl compound in a single formulation is preferred.


The combination is particularly effective against Siphonaptera (fleas), and Acarina (ticks and mites). Surprisingly, the combination has been found to be particularly effective against the species of ticks on dogs,
15 *Demacentor variabilis* and *Rhipicephalus sanguineus*. The results are unexpected because the agonist or antagonists of acetylcholine receptors of insects such as imidacloprid have no appreciable activity against acarids such as ticks and mites; yet the combination thereof with permethrin results in a substantially enhanced activity against these
20 parasites. Additionally, the exceptional activity of chloronicotinyl compounds against fleas is not reduced.

The composition according to the invention may additionally comprise other active ingredients such as insect growth regulants (pyriproxyfen, methoprene, which do not interfere with the preparation or
25 efficacy of the combination.

Active compounds which can be used for the purposes of the invention include imidacloprid, AKD 1022 and Ti 435.

AKD 1022 is a chloronicotinyl derivative of the formula


5



10

Ti 435 is a chloronicotinyl derivative of the formula

15



In the examples which follow, the active compounds employed are
 20 [(3-phenoxyphenyl)methyl-3-92,2-dichlorovinyl]-2,2-dimethylcyclo-
 propanecarboxylate] having the common name permethrin and 1-[(6-
 chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine having the common
 name imidacloprid.

The invention is further illustrated but is not intended to be limited
 25 by the following examples in which all parts and percentages are by weight
 unless otherwise specified.

EXAMPLES

Example 1

30 The purpose of this study was to was to determine comparative
 flea and tick control over a 30 day interval of a combination application of a
 pyrethroid and a chloronicotinyl insecticide applied dermally to dogs. This
 combination was compared with permethrin alone, imidacloprid alone,
 fipronil and selamectin. The latter two compounds are present in products
 35 that currently carry claims for both tick and flea control

Thirty-six dogs were divided into six groups of 6 dogs per group.
 Each dog received a single topically-applied treatment of the either "Kiltix",
 a product available from Bayer Corporation containing 45% w/w

permethrin, Advantage®, a product available from Bayer Corporation containing 9.1% w/w imidacloprid, a combination of Kiltix and Advantage containing 45% w/w permethrin + 9.1%w/w imidacloprid, Top Spot®, a product available from Merial containing 9.7% fipronil or Revolution®, a 5 product available from Pfizer Inc. containing 12% w/v selamectin in accordance with the appropriate dose and label instructions for the various product applications. Control dogs remained untreated. All products were provided in the commercial unit dose applicator tubes.

The dogs were bathed with a mild non-medicated shampoo and 10 thoroughly combed to remove any existing fleas or ticks 7 to 14 days prior to treatment. The dogs were infested with 100 unfed adult ticks (50 *Dermacentor variabilis* and 50 *Rhipicephalus sanguineus*) and 100 unfed adult fleas on Day -3. Live fleas and ticks were counted on Day -1. The dogs were ranked according to total pretreatment live tick counts from 15 highest to lowest. The 36 dogs with the highest counts were selected for the study. Each consecutive group of 6 dogs comprised one block. Treatment was randomly assigned within each block of dogs.

Each dog was examined visually for fleas and ticks on Days 1, 7, 14, 21, and 28 following treatment . The hair was parted with the thumbs 20 and fingers to count fleas and ticks. Live tick counts were recorded by species. Live ticks only were counted visually on Days 2, 8, 15, 22, and 29. The dogs were combed on Days 3, 9, 16, 23, and 30. All remaining live fleas and ticks were counted and removed.

The dose for the various compounds is provided in Table 1.

Table 1 Dose of Compounds Dermally Applied to Dogs

Group	Treatment	Dose	Application
1	45% Permethrin	<33 lbs = 1.5 mL >33 lbs = 2x1.5 mL	<33 lbs: 1.5 mL of solution on the back between the shoulder blades > 33 lbs : 1.5 mL between the shoulder blades + 1.5 mL on the rump at the base of the tail
2	9.1% Imidacloprid	< 10 lb = 0.4 mL 11-20 lb = 1.0 mL	On the back to one spot between the shoulder blades
		21 – 55 lb = 2.5 mL >55 lb = 4.0 mL	Apply evenly to 3-4 spots on the back between shoulder to base of tail
3	45% Permethrin + 9.1% Imidacloprid	Same as above for both products	Apply according to above directions but do not apply both products to the same spot
4	9.7% fipronil	<22 lbs = 0.67 mL 23-44 lbs = 1.3 mL 45-48 lbs = 2.68 mL	Apply contents of tube on the skin at one spot between the shoulder blades
5	12% Selamectin (120 mg/mL)	10.1 – 20 lb = 0.5 mL 20.1 – 40 lb = 1.0 mL 40.1 – 85 lb = 2.0 mL	Apply contents of tube on the skin at one spot between the shoulder blades
6	Control	No Treatment	

The results of this study are shown in Table 2, 3 and 4.

Table 2
COMPARATIVE EFFICACY
D. VAR/ABI/L/S
PERCENT CONTROL

Study Day	Imidacloprid	Permethrin	Imidacloprid + Permethrin	Fipronil	Selamectin
1	-12.0	36.2	64.2	*92.9	26.2
2	16.9	53.9	81.9	*100	46.7
3	30.9	75.3	96.4	100	70.8
7	32.5	95.2	97.0	100	23.1
8	35.3	96.1	98.4	100	61.2
9	39.4	97.1	98.6	100	83.2
14	50.3	91.5	97.4	98.7	16.6
15	66.4	92.9	99.2	100	32.7
16	68.4	96.8	99.2	100	46.1
21	50.2	90.8	87.7	92.7	2.7
22	40.1	85.1	94.5	98.7	-0.6
23	50.2	89.3	97.7	100	24.7
28	38.8	79.3	**91.8	69.7	0.1

*Fipronil significantly different than Imidacloprid + Permethrin
 ** Imidacloprid + Permethrin significantly different than Fipronil

Table 3
COMPARATIVE EFFICACY
R. SANGUINEUS
PERCENT CONTROL

Study Day	Imidacloprid	Permethrin	Imidacloprid + Permethrin	Fipronil	Selamectin
1	15.5	72.7	76.8	96.3	-13.1
2	42.4	75.0	85.9	100	48.5
3	35.9	85.0	91.8	100	87.4
7	67.2	99.4	98.9	100	83.9
8	72.0	100	100	100	83.6
9	66.6	99.0	100	100	95.6
14	53.5	95.2	95.2	99.4	21.5
15	58.2	98.9	98.2	100	46.0
16	54.0	99.4	98.4	99.4	70.9
21	41.5	89.4	87.0	86.0	-7.0
22	18.9	91.7	91.8	100	-2.2
23	-5.3	91.5	99.0	100	8.2
28	39.1	68.6	84.6	65.3	-16.0

TABLE 4
COMPARATIVE EFFICACY
FLEAS (*Siphonaptera*)
PERCENT CONTROL

Day	Permethrin	Imidacloprid	Imidacloprid + Permethrin	Fipronil	Selamectin
-1	1.5	5.4	27.7	22.4	15.1
1	89.8	100	100	100	87.3
3	93.9	100	100	100	100
7	79.4	100	100	100	100
9	87.8	100	100	100	100
14	71.9	100	100	100	99.7
16	65.1	100	100	100	100
21	52.9	100	99.8	100	99.8
23	41.9	99.6	100	100	100
28	43.9	98.6	98.4	100	86
30	7.7	99.4	98.7	100	98

The following significant conclusions can be drawn from this study.

1. The combination of permethrin and imidacloprid produced a faster kill of both species of ticks (*D. variabilis* and *R. sanguineus*) than either permethrin or imidacloprid alone. The combination provided 82 to 86% killing of ticks by day 2 post application and approximately 100% killing of both species of ticks by day 3 post application. Permethrin alone required 7 days to approach a 100% killing of ticks. Selamectin required 9 days to reach only an 83% killing of *D. variabilis*, and then this compound lost its activity.
- 5 10 Selamectin produced earlier killing of *R. sanguineus* (87% by day 3), however, the tick killing of selamectin decreased rapidly and was negligent by day 16 post application. Fipronil produced an early kill, similar to that of the combination of permethrin and imidacloprid.
- 15 20 2. The length of time that significant tick control occurred with the combination of permethrin and imidacloprid was significantly longer than that of permethrin alone, imidacloprid alone, selamectin or fipronil. The data indicate that the combination of permethrin and imidacloprid controlled 85 to 92 % of both species of ticks by 28 days post application.
- 25 30 3. The killing of fleas on dogs remained unaffected by the presence of permethrin in the formulation. Table 4 indicates that permethrin alone had some killing effect on fleas from day 1 through day 21 whereas imidacloprid killed essentially all of the fleas from day 1 through day 30. The combination of permethrin and imidacloprid demonstrated an equally effective killing of fleas from day 1 through day 30. Selamectin was not as effective as either imidacloprid or the combination of imidacloprid and permethrin. The latter compound required 3 days to demonstrate a significant killing of fleas and then this killing effect appeared to fall by 28 days post application. Fipronil demonstrated a rate of flea kill equal to that of imidacloprid or the combination of imidacloprid and permethrin.

4. The rapid onset of killing of both fleas and ticks by the combination of permethrin and imidacloprid indicates that there was effective spreading of both active ingredients.
5. The length of time that the combination remained active against both species of ticks and fleas indicates that there is adequate distribution of the active ingredients into the skin of the animals.

The foregoing shows that a combination of a pyrethroid and a chloronicotinyl compound produces a synergistic effect against killing ticks and remains effective against killing of fleas. The killing effects on ticks 10 began earlier and lasted longer with the combination than with either the permethrin or imidacloprid alone.

Example 2

The above study incorporated an evaluation of safety of the various 15 compounds. This was determined by examination of the skin at the site(s) of application and the behaviour of the dogs post application. None of the formulations produced an irritation at the site of application and none of the dogs demonstrated discomfort post application. Therefore, it was determined that the combination of permethrin and 20 imidacloprid was safe, non-irritating and effective against ticks and fleas. It would be expected to be effective against mites as they have a response similar to ticks.

Although the invention has been described in detail in the foregoing for the purpose of illustration, it is to be understood that such detail is 25 solely for that purpose and that variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention except as it may be limited by the claims.

WHAT IS CLAIMED IS:

1. A composition for control of parasitic insects and acarids comprising a combination of a pyrethroid and a nicotinyl compound.
2. The composition of Claim 1 wherein in the pyrethroid is in 5 a concentration of from 0.1 to 60% by weight and the nicotinyl compound is in a concentration of 0.001 to 25% by weight, based on the overall weight of the combination.
3. The composition of Claim 1 wherein the pyrethroid is permethrin.
- 10 4. The composition of Claim 1 wherein the nicotinyl compound is imidacloprid.
5. The composition of Claim 1 comprising permethrin and imidacloprid.
6. A formulation for dermal control of parasitic insects and 15 acarids comprising the combination of Claim 1, a solvent and optionally an auxiliary.
7. A method of preparing the composition as recited in Claim 1, comprising mixing the pyrethroid and nicotinyl compound.
8. A method of preparing the formulation of Claim 6, 20 comprising mixing the pyrethroids, the nicotinyl compound, the solvent, and optionally the auxiliary.
9. A process of treating a mammal or premise infected with insects and acarids comprising administering to the mammal or premise with the composition of Claim 1.
- 25 10. A process of treating a mammal or premise infected with insects and acarids comprising administering to the mammal or premise with the formulation of Claim 6.

This Page Blank (uspto)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/043494 A3

(51) International Patent Classification⁷: A01N 53/00 // (A01N 53/00, 51:00)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US01/44084

(22) International Filing Date:
26 November 2001 (26.11.2001)

(25) Filing Language:

English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
09/727,117 30 November 2000 (30.11.2000) US

Published:
— with international search report

(71) Applicant: BAYER CORPORATION [US/US]; 100
Bayer Road, Pittsburgh, PA 15205-9741 (US).

(88) Date of publication of the international search report:
22 August 2002

(72) Inventor: ARTHER, Robert, G.; 8103 Sagamore, Leawood, KS 66206 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: AKORLI, Godfried, R. et al.; Bayer Corporation, 100 Bayer Road, Pittsburgh, PA 15205-9741 (US).



WO 02/043494 A3

(54) Title: COMPOSITIONS FOR ENHANCED ACARICIDAL ACTIVITY

(57) Abstract: A composition for control of parasitic insects and acarids, comprising a combination of pyrethroids and chloronicotinyl compounds.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/44084

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A01N53/00 // (A01N53/00, 51:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
 IPC 7 A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, CHEM ABS Data, CAB Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 17520 A (BAYER AG ;SIRINYAN KIRKOR (DE); DORN HUBERT (DE); KUJANEK RICHARD) 13 June 1996 (1996-06-13) page 1, line 13 -page 2, line 7 page 6, line 5 - line 17 page 10, line 17 -page 11, line 23 page 12, line 12 -page 13, line 5 page 22; example 13 --- EP 0 387 663 A (BAYER AG) 19 September 1990 (1990-09-19) page 2, line 26 -page 3, line 5 page 8, line 1 - line 29 --- -/--	1,2,4, 6-10
X		1-5,7

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

10 May 2002

Date of mailing of the international search report

31/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
 Fax. (+31-70) 340-3016

Authorized officer

Lamers, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/44084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 198827 Derwent Publications Ltd., London, GB; Class C02, AN 1988-188015 XP002198553 & JP 63 126805 A (NIHON TOKUSHU NOYAKU SEIZO KK), 30 May 1988 (1988-05-30) abstract ---	1-5,7
X	US 5 661 164 A (OTSU YUICHI ET AL) 26 August 1997 (1997-08-26) column 9; example 1 ---	1-5,7
P,X	DATABASE CROPU 'Online! R.ARTHUR ET AL.: "Comparative evaluation of topically applied imidacloprid, permethrin, selamectin and fipronil for control of fleas and ticks on dogs" retrieved from STN-INTERNATIONAL, accession no. 2002-81364 CROPU XP002198549 abstract & PROC.AM.ASSOC.VET.PARASITOL. (46 MEET., 38, 2001), ---	1-10
P,X	US 6 218 416 B1 (SEMBO SATOSHI) 17 April 2001 (2001-04-17) column 1, line 19 - line 28 column 2, line 4 - line 18 column 4, line 61 -column 5, line 9 column 5, line 40 - line 53 column 6, line 39 - line 47 column 7, line 66 -column 8, line 2 column 8, line 9 - line 24 ---	1,2,6-10
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; A.LIEBISCH ET AL.: "The efficacy of imidacloprid against flea infestation on dogs compared with three other topical preparations" retrieved from EPOQUE, accession no. PREV200000261492 XP002198550 abstract & CANINE PRACTICE, vol. 25, no. 2, April 2000 (2000-04), pages 8-11, ---	1-10
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/44084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE MEDLINE 'Online! M.FRANC ET AL.: "Activity of deltamethrin shampoo against Ctenocephalides felis and Rhipicephalus sanguineus in dogs" retrieved from EPOQUE, accession no. nlm10206106 XP002198551 abstract & VETERINARY PARASITOLOGY, vol. 81, no. 4, 15 March 1999 (1999-03-15), pages 341-346, -----</p>	1-10
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; W.J.GLADNEY ET AL.: "THE BROWN TICK LABORATORY TESTS OF ACARICIDES" retrieved from EPOQUE, accession no. PREV197764013791 XP002198552 abstract & SOUTHWESTERN ENTOMOLOGIST, vol. 1, no. 4, 1976, pages 184-189, -----</p>	1-10
A	<p>EP 0 682 869 A (BAYER AG) 22 November 1995 (1995-11-22) page 2, line 14 -page 4, line 50 page 6, line 19 -page 8, line 36 page 14, line 15 - line 18 page 15, line 16 -----</p>	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/44084

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9617520	A	13-06-1996	DE 4443888 A1 AT 176383 T AU 701461 B2 AU 4256996 A BR 9509873 A CA 2207212 A1 CN 1175188 A CZ 9701727 A3 DE 59505055 D1 DK 796042 T3 WO 9617520 A1 EP 0796042 A1 ES 2126958 T3 FI 972387 A GR 3029907 T3 HU 77235 A2 JP 3257679 B2 JP 10510252 T NO 972592 A NZ 297416 A PL 320674 A1 SK 71797 A3 US 6372765 B1 US 6001858 A ZA 9510433 A	13-06-1996 15-02-1999 28-01-1999 26-06-1996 25-11-1997 13-06-1996 04-03-1998 15-10-1997 18-03-1999 20-09-1999 13-06-1996 24-09-1997 01-04-1999 05-06-1997 30-07-1999 02-03-1998 18-02-2002 06-10-1998 04-08-1997 24-09-1998 27-10-1997 08-10-1997 16-04-2002 14-12-1999 18-06-1996
EP 0387663	A	19-09-1990	DE 3908814 A1 DE 4000972 A1 AU 633883 B2 AU 5141890 A CN 1045505 A DE 59002510 D1 EP 0387663 A1 JP 2273601 A NZ 232910 A ZA 9002030 A	20-09-1990 18-07-1991 11-02-1993 20-09-1990 26-09-1990 07-10-1993 19-09-1990 08-11-1990 28-10-1992 28-12-1990
JP 63126805	A	30-05-1988	JP 2050660 C JP 7084365 B	10-05-1996 13-09-1995
US 5661164	A	26-08-1997	JP 8099809 A US 5880142 A	16-04-1996 09-03-1999
US 6218416	B1	17-04-2001	AU 2764600 A BR 0001661 A CN 1271521 A IT T020000371 A1	26-10-2000 31-10-2000 01-11-2000 19-10-2001
EP 0682869	A	22-11-1995	DE 4417742 A1 AU 696581 B2 AU 2014495 A CA 2149594 A1 CZ 9501309 A3 EP 0682869 A1 FI 952421 A HU 71902 A2 IL 113756 A JP 8092091 A	23-11-1995 17-09-1998 30-11-1995 21-11-1995 13-05-1998 22-11-1995 21-11-1995 28-02-1996 28-10-1999 09-04-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/44084

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0682869	A	NO 951993 A	21-11-1995
		NZ 272141 A	28-10-1996
		PL 308664 A1	27-11-1995
		RU 2166253 C2	10-05-2001
		SK 66395 A3	06-12-1995
		US 2001027201 A1	04-10-2001
		US 2001044456 A1	22-11-2001
		US 2001041723 A1	15-11-2001
		US 6329374 B1	11-12-2001
		US 2001021716 A1	13-09-2001
		US 6232328 B1	15-05-2001
		ZA 9504107 A	19-01-1996